共 96 条
[11]
Ivergård M(2020)Endocrinology in the time of COVID-19: management of hyperthyroidism and hypothyroidism Eur J Endocrinol 183 G57-G65
[12]
Biarnés-Suñé A(2020)Endocrinology in the time of COVID-19: management of pituitary tumours Eur J Endocrinol 42 52-62
[13]
Solà-Enríquez B(2020)Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia Eur J Endocrinol 102 607-618
[14]
González Posada MÁ(2020)Management of calcium metabolic disorders and osteoporosis Eur J Endocrinol 102 501-502
[15]
Pluskiewicz W(2012)Skeletal and extraskeletal actions of denosumab Endocrine 56 138-826
[16]
Wilk R(2018)Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton Calcif Tissue Int 40 825-205
[17]
Adamczyk P(2018)Osteoimmunology Calcif Tissue Int 70 203-97
[18]
Ojeda-Thies C(2020)Alarmins in osteoporosis, RAGE, IL-1, and IL-33 pathways: a literature review Medicina (B Aires) 85 78-624
[19]
Cuarental-García J(2020)Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs Rheumatol Int 70 617-346
[20]
Ramos-Pascua LR(2020)Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 18 335-13